The tumor suppressor p53 is a transcription factor that controls the expression of hundreds of genes. Emerging evidence suggests that the p53-induced RNA-binding protein ZMAT3 is a key splicing ...

As of June 18, 2025, RNA has a market capitalization of $3.539 billion, reflecting investor confidence in its pipeline and technology platform. The company’s financial position appears solid, with ...

Laiho holds patents on RNA polymerase 1 inhibitors, which are managed by The Johns Hopkins University in accordance with its conflict-of-interest policies.

The limited therapeutic options against the influenza virus (flu) and increasing challenges in drug resistance make the search for next-generation agents imperative. In this context, heterotrimeric ...